SCHEMBL12050451

SCHEMBL12050451

COc1ccccc1P(Cc1ccccc1P(c1ccccc1)c1ccccc1)c1ccccc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
CHRM2 P08172 3/20 0.37
CHRM1 P11229 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
ABCB1 P08183 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14257174 0.95 IDO1 (0.37) IDO1TAAR1CHRM2CHRM1L3MBTL1
SCHEMBL12050455 0.85 IDO1 (0.41) IDO1TAAR1CHRM2CHRM1L3MBTL1
SCHEMBL2824504 0.85 CA12 (0.46) IDO1TAAR1CHRM2CHRM1L3MBTL1
SCHEMBL56425 0.81 CA1 (0.50) L3MBTL1SMN1; SMN2HTTCA12CA1
SCHEMBL8459532 0.79 CA1 (0.48) L3MBTL1SMN1; SMN2HTTCA12CA1
SCHEMBL476857 0.77 CA1 (0.50) L3MBTL1SMN1; SMN2HTTCA12CA1
SCHEMBL30992110 0.77 CA1 (0.50) L3MBTL1SMN1; SMN2HTTCA12CA1
SCHEMBL25208290 0.76 CA1 (0.44) IDO1TAAR1CHRM2CHRM1L3MBTL1
SCHEMBL903333 0.76 CA1 (0.44) IDO1TAAR1CHRM2CHRM1L3MBTL1
SCHEMBL31593 0.76 CA1 (0.44) IDO1TAAR1CHRM2CHRM1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404915-B2 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-03-26 US disclosed
US-8404915-B2 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-03-26 US disclosed
US-8076524-B2 Process for generating alpha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-12-13 US disclosed
US-8076524-B2 Process for generating alpha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-12-13 US disclosed
US-8003839-B2 Process for generating linear apha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-23 US disclosed
US-8003839-B2 Process for generating linear apha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-08-23 US disclosed
US-7982085-B2 In-line process for generating comonomer EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-07-19 US disclosed
US-7982085-B2 In-line process for generating comonomer EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-07-19 US disclosed
US-20080058486-A1 Phosphine Ligand-Metal Compositions, Complexes, and Catalysts For Ethylene Trimerizations SYMYX TECHNOLOGIES INC. 2008-03-06 US disclosed
US-20080058486-A1 Phosphine Ligand-Metal Compositions, Complexes, and Catalysts For Ethylene Trimerizations SYMYX TECHNOLOGIES INC. 2008-03-06 US disclosed
US-20070185360-A1 Process for generating linear apha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. 2007-08-09 US disclosed
US-20070185360-A1 Process for generating linear apha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. 2007-08-09 US disclosed
US-20070185362-A1 Process for generating alpha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. 2007-08-09 US disclosed
US-20070185362-A1 Process for generating alpha olefin comonomers EXXONMOBIL CHEMICAL PATENTS INC. 2007-08-09 US disclosed
US-20070185361-A1 In-line process for generating comonomer EXXONMOBIL CHEMIAL PATENTS INC. 2007-08-09 US disclosed
US-20070185361-A1 In-line process for generating comonomer EXXONMOBIL CHEMIAL PATENTS INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185360-A1 Process for generating linear apha olefin comonomers ACMSD, AGL, ACSL4 IDO1 3281/4885TAAR1 1893/4885CHRM2 2636/4885
US-20070185361-A1 In-line process for generating comonomer ELL, SAMM50, AGL IDO1 3791/4885TAAR1 1725/4885CHRM2 3193/4885
US-20070185362-A1 Process for generating alpha olefin comonomers ETFA, ETFB, SAMM50 IDO1 3794/4885TAAR1 2372/4885CHRM2 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.